Glaxo withdraws Lotronex from market

At the request of the FDA, Glaxo (GLX; LSE:GLXO) withdrew from the U.S. market its Lotronex alosetron selective 5-HT3 receptor antagonist to treat diarrhea-predominant irritable bowel syndrome (IBS) i...